Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ZonMw: The Netherlands Organisation for Health Research and Development | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The standard surgical treatment for glaucoma is trabeculectomy. The PRESERFLO™ (formerly InnFocus) Microshunt (IMS) is a new, minimally invasive drainage device which has been suggested to result in similar IOP lowering, but with faster visual recovery and less complications and postoperative interventions. The objective of this study is to aid in deciding on the use of the IMS in glaucoma surgery by assessing its efficacy and cost-effectiveness in patients with primary open angle glaucoma (POAG) compared to the standard trabeculectomy (TE).
During the last decade, minimally invasive glaucoma surgery (MIGS) procedures have been introduced to the market. MIGS procedures or devices, often small stents or tubes that can be placed into the eye, are potentially safer than standard trabeculectomy (TE). The surgery is faster and easier to perform. Patient recovery is faster with fewer postoperative visits, suggesting less impact on vision and quality of life. However, MIGS devices are more expensive compared to standard surgery and it is unclear if the higher costs can be compensated with their better safety profile and faster patient recovery (reduced productivity losses).
To establish guidelines for the use of MIGS, the Netherlands Glaucoma Group has recognized the need for a formal investigation of their cost-effectiveness as compared to TE, prior to their implementation on a large scale for regular care. Therefore, a societal cost-effectiveness analysis of MIGS procedures will be undertaken to further elucidate their position in the glaucoma treatment algorithm in the Netherlands.
The objective of this study is to aid in deciding on the use of the IMS in glaucoma surgery by assessing its efficacy and cost-effectiveness in patients with primary open angle glaucoma compared to trabeculectomy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS)) | Active Comparator | The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS). |
|
| Trabeculectomy | Active Comparator | The usual care/control group will undergo a standard trabeculectomy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PRESERFLO Microshunt implantation | Procedure | The intervention consists of the microshunt implantation augmented with mitomycin C application. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intraocular pressure | The intraocular pressure is measured using a Goldmann applanation tonometer | 12 months postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Visual acuity | Measured with ETDRS letter charts | baseline, 1 week, 4 weeks, 3, 6, 9 and 12 months postoperatively |
| Glaucoma medical therapy | number of glaucoma drugs (active substances) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patient unwilling or unable to give informed consent, unwilling to accept randomization or inability to complete follow-up (e.g. hospital visits) or comply with study procedures
Secondary glaucoma (e.g. pigment dispersion syndrome, pseudo exfoliation syn-drome, iris neovascularization, rubeosis iridis, trauma, epithelial or fibrous down growth, iridocorneal endothelial syndrome, etcetera).
Previous incisional surgery of the subject eye. Previous uncomplicated clear corneal cataract surgery is allowed >6 months prior to the surgery.
Poor vision in either the study or fellow eye. Poor vision is defined as a corrected vis-ual acuity <0.6 and/or a visual field loss within the central 10 degrees (with exception of a superior altitudinal defect).
Any ocular comorbidities that could affect the visual field. (e.g. diabetic retinopathy, proliferative retinopathy, aphakia, degenerative visual disorder not associated with glaucoma)
Chronic or recurrent uveitis.
Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery.
Anatomical factors that increase the risk of complicated surgery (due to previous trauma, anatomical abnormalities, anterior synechiae or previous cyclodestructive procedure).
Conditions that increase the risk of endophthalmitis.
Contraindication or allergy to mitomycin C.
Any contraindication to tube placement (e.g. shallow anterior chamber, insufficient endothelial cell density).
Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
Prior ocular laser treatment within 3 months of the surgery, increasing the risk of in-flammation in the eye.
Corneal thickness <450um or >620microns.
Conditions associated with elevated episcleral venous pressure such as active thyroid orbitopathy.
Among patients in whom both eyes are eligible only the first eye is undergoing surgical treatment is enrolled in the study.
Participation in another clinical study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Henny Beckers, MD, PhD | Maastricht University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center+ (MUMC+) | Maastricht | Limburg | 6229HX | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36721130 | Derived | Scheres LMJ, van den Biggelaar FJHM, Winkens B, Kujovic-Aleksov S, Muskens RPHM, de Waard PWT, de Crom RMPC, Ernest PJG, Pijl BJ, Ramdas WD, van Rijn LJ, Tan A, Dirksen CD, Beckers HJM. Effectiveness and cost-effectiveness of MicroShunt implantation versus standard trabeculectomy for open-angle glaucoma (a SIGHT study): study protocol of a multicentre randomised controlled trial. BMC Ophthalmol. 2023 Jan 31;23(1):43. doi: 10.1186/s12886-022-02734-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005902 | Glaucoma, Open-Angle |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D009798 | Ocular Hypertension |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014130 | Trabeculectomy |
| ID | Term |
|---|---|
| D018463 | Filtering Surgery |
| D013508 | Ophthalmologic Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Trabeculectomy | Procedure | The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application. |
|
| at baseline and 1 day, 1 week, 4 weeks, 3, 6, 9 and 12 months postoperatively |
| Failure rate | Failure is defined as an IOP >21 mmHg and ≤ 5 mmHg or less than 20% reduction relative to baseline IOP at two consecutive follow-up visits after 3 months. Reoperation will also be defined as failure. | 3, 6, 9 and 12 months postoperatively |
| Complications | The incidence of intraoperative and postoperative complications. | Intraoperatively and up to 12 months after the surgery. |
| Reinterventions | The number of reinterventions after the surgery. | Measured up to 12 months after the surgery. |
| Visual field progression | The progression seen on the visual field. | measured twice at baseline and twice after 12 months of follow-up. |
| Mean endothelial cell loss | The endothelial cell density will be measured using specular microscopy photography. | measured at baseline and after 12 months of follow-up. |
| Patient- reported outcome measures (PROMs): NEI-VFQ-25 | Patient satisfaction and vision-specific quality of life as measured by National Eye Institute Visual Function Questionnaire (NEI VFQ-25). | measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively |
| Patient- reported outcome measures (PROMs): GQL-15 | Patient satisfaction and vision-specific quality of life as measured by Glaucoma Quality of Life-15 (GQL-15). | measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively |
| Patient- reported outcome measures (PROMs): EuroQol's EQ-5D-5L | Health-related quality of life as measured by EuroQol's EQ-5D-5L questionnaire. | measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively |
| Patient- reported outcome measures (PROMs): HUI3 | Health-related quality of life as measured by HUI3 (Health Utility Index Mark 3) questionnaire. | measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively |
| Quality Adjusted Life Years (QALYs) | Calculated based on generic health-related quality of life, using the EQ-5D-5L and HUI-3 questionnaires | Baseline until 12 months postoperatively |
| Costs per patient | Cost per patient, including valuation of resource use by using the Dutch guidelines for cost-analyses or cost prices provided by the medical center. | Baseline until 12 months postoperatively |
| Incremental cost-effectiveness ratios (ICERs): QALY | Evaluation of cost-effectiveness by using calculated costs per quality-adjusted life years (QALYs) | Baseline until 12 months postoperatively |
| Incremental cost-effectiveness ratios (ICERs): NEI VFQ-25 | Calculated costs per clinically improved patient on the NEI VFQ-25 questionnaire | Baseline until 12 months postoperatively |
| Incremental cost-effectiveness ratios (ICERs): GQL-15 | Calculated costs per clinically improved patient on the GQL-15 questionnaire | Baseline until 12 months postoperatively |
| Incremental cost-effectiveness ratios (ICERs): IOP | Calculated costs per patient with clinically lowered IOP | Baseline until 12 months postoperatively |
| Budget impact | Reported as a difference in costs. Different scenario's will be compared to investigate the impact of various levels of implementation (e.g. 25%, 50%, 75% of eligible patients). | Baseline until 12 months postoperatively |